| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 14,162,046 | 14,253,662 |
| Net change in cash and cash equivalents | 3,402,709 | 5,668,495 |
| Cash and cash equivalents at beginning of period | 6,461,378 | - |
| Cash and cash equivalents at end of period | 9,864,087 | - |
CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc. (CNSP)